Our Microbiome Innovations Transform Patient Care
We founded Seed Health to realize the microbiome as a radical new pathway for well-being. We pioneer breakthrough research to develop clinically validated probiotics, prebiotics, and postbiotics to optimize the development and maturation of the human microbiome from conception through healthy aging. We're on a mission to set a new standard and evolve our paradigms of care.
DS-01® Benefits In and Beyond the Gut
Our flagship innovation, DS-01® Daily Synbiotic, is now available for your healthcare practice. Developed from a deep understanding of the complex interactions within the microbiome, our broad-spectrum synbiotic (53.6 billion AFU) is formulated for benefits in and beyond the gut with a polyphenol-based prebiotic and 24 distinct, clinically and scientifically studied probiotic strains.*
Based on three double-blind, randomized, placebo-controlled trials, DS-01® has no serious adverse effects and is efficacious for supporting gastrointestinal health through ease of evacuation, bloating, gas production, abdominal pain, serotonin production, and the recovery of low-abundance species during and after a course of broad-spectrum antibiotics. DS-01® has published data supporting delivery at 100% potency of the declared probiotic species (53.6 billion AFU) through the entire gastrointestinal system, with a complete release in the small intestine, under both fed and fasted conditions.*
Recommend Seed Synbiotics to Your Patients with Fullscript
Seamlessly access Seed synbiotics through Fullscript® for direct delivery to your patients or convenient distribution from your office.
Recommend Seed on Fullscript®Grow with Seed
Our resources and healthcare education are designed to empower practitioners across the patient journey.
Enrich Your Microbiome Education
With a deep commitment to education and to providing actionable insights, we translate foundational concepts, our latest research, and discoveries from the frontlines of microbiome science.
Sign up for EducationConnect with our Practitioner Team
The skilled clinicians on our team are here to answer your questions and provide the information you need to make important patient decisions. We collaborate closely with our R+D team to provide clinician-to-clinician responses.
Connect with Clinical Specialists Select Clinical + Scientific
Board Members
Emeran Mayer, MD
Belinda Tan, MD, PhD
Jacques Ravel, PhD
Kari Nadeau, MD, PhD, FAAAAI
Microbial Innovation From Discoveryto Impact
We are a diverse, interdisciplinary collective of scientists, practitioners, designers, engineers, bioinformaticians, operators, and scientific communicators.
We advance frontier microbiome science from discovery to real-world impact to develop breakthrough innovations in biotics, living medicines, and environmental solutions.
Our development programs power a pipeline of innovations that encompass areas of health beyond the gut microbiome, including the vaginal microbiome, skin microbiome, oral microbiome, infant health, and the gut-brain axis.
FAQs
We've partnered with Fullscript® for direct delivery to your patients or convenient distribution from your office—click here.
We developed DS-01® to deliver benefits in and beyond the gut to support the physiological systems essential to our whole-body health. Intended for use by adults 18 and older, DS-01® contains a polyphenol-based prebiotic and 24 distinct probiotic strains to support:
As part of our mission to create a new standard in probiotics, DS-01® undergoes extensive and frequent third-party testing, which includes: flow cytometry to measure and enumerate viable cells; survivability testing to validate probiotic survival through digestive conditions; heat and humidity testing to mimic the most extreme conditions our product may encounter during shipping and storage; and over 50 quality assurance and quality control (QA/QC) checkpoints.
To validate survivability, Seed tests with the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®)—the closest system developed to model human digestion and the gut. This simulator recreates the physiological conditions and biological processes (food uptake, peristalsis, pancreatic and digestive enzymes, bile acids, and time spent in each step) representative of the human gastrointestinal tract.
DS-01® stands on a foundation of rigorous scientific validation, with 10 clinical trials and 14 pre-clinical trials underpinning our strain-specific benefits. We have also completed three additional double-blind, randomized, placebo-controlled trials on DS-01®, including one under an investigational new drug (IND) application. Our research protocols and endpoints are designed with leading scientific and medical key opinion leaders.*
Based on three double-blind, randomized, placebo-controlled trials, DS-01® has no serious adverse effects and is efficacious for supporting gastrointestinal health through ease of evacuation, bloating, gas production, abdominal pain, serotonin production, and the recovery of low-abundance species during and after a course of broad-spectrum antibiotics. DS-01® has published data supporting delivery at 100% potency of the declared probiotic species (53.6 billion AFU) through the entire gastrointestinal system, with a complete release in the small intestine, under both fed and fasted conditions.*
Real clinicians,
here to support.
Our Practitioner Team is here ready to help you integrate DS-01® into your practice.
Ready to learn more?
Access practitioner resources, and your complimentary DS-01® product trial.
